𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Chronic myelogenous leukemia in chronic phase

✍ Scribed by Razelle Kurzrock; Hagop Kantarjian; Moshe Talpaz

Book ID
107531715
Publisher
Springer
Year
2001
Tongue
English
Weight
220 KB
Volume
2
Category
Article
ISSN
1527-2729

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Persistent neutropenia in chronic myelog
Persistent neutropenia in chronic myelogenous leukemia in chronic phase treated with imatinib mesylate
✍ Yu-Yan Hwang; Eric Tse; Jason C.C. So; Thomas S.K. Wan; Yok-Lam Kwong πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 110 KB πŸ‘ 1 views

A physician or a group of physicians considers presentation and evolution of a real clinical case, reacting to clinical information and data (boldface type). This is followed by a discussion/commentary.

The significance of myelosuppression dur
The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase
✍ Thomas B. Sneed; Hagop M. Kantarjian; Moshe Talpaz; Susan O'Brien; Mary Beth Rio πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 82 KB πŸ‘ 1 views

## Abstract ## BACKGROUND Imatinib mesylate induces high rates of hematologic and cytogenetic response in patients with chronic myelogenous leukemia (CML). During therapy with imatinib, up to 45% of patients with CML reportedly experience myelosuppression β‰₯ Grade 3, requiring interruption of thera

Phase 1 study of tipifarnib in combinati
Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure
✍ Jorge Cortes; Alfonso QuintΓ‘s-Cardama; Guillermo Garcia-Manero; Susan O'Brien; D πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 92 KB πŸ‘ 2 views

## Abstract ## BACKGROUND. The tolerability and efficacy of the combination of tipifarnib, an orally bioavailable nonpeptidomimetic farnesyl transferase inhibitor, and imatinib was investigated in patients with chronic myelogenous leukemia in chronic phase who had failed imatinib. ## METHODS. Tw

Chromosomal abnormalities in Philadelphi
Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase
✍ Jorge Medina; Hagop Kantarjian; Moshe Talpaz; Susan O'Brien; Guillermo Garcia-Ma πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 107 KB

## Abstract ## BACKGROUND Anecdotal cases of chromosomal abnormalities in Philadelphia chromosome (Ph)‐negative metaphases have been reported in patients with chronic myelogenous leukemia (CML) in the chronic phase during treatment with interferon and, more recently, with imatinib. This phenomenon